Rahel Ghebre

Rahel Ghebre

Auto-generated profile, based on publicly available information

Rahel Ghebre

University of Minnesota, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
RGRahel G. Ghebre
Rahel G. Ghebre
SGSurbhi Grover
Surbhi Grover
MXMelody J. Xu
Melody J. Xu
LCLinus T. Chuang
Linus T. Chuang
HSHannah Simonds
Hannah Simonds
Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.

7 November 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
HLHee Yun Lee
Hee Yun Lee
RGRahel Ghebre
Rahel Ghebre
CLChap Le
Chap Le
YJYoo Jeong Jang
Yoo Jeong Jang
MSMonica Sharratt
Monica Sharratt
DYDouglas Yee
Douglas Yee
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
VVVerna D. Vanderpuye
Verna D. Vanderpuye
JCJean Rene V. Clemenceau
Jean Rene V. Clemenceau
STSarah Temin
Sarah Temin
ZAZeba Aziz
Zeba Aziz
WBWilliam M. Burke
William M. Burke
RGRahel G. Ghebre
Rahel G. Ghebre
PURPOSE: To provide expert guidance to clinicians and policymakers in three resource-constrained settings on diagnosis and staging of adult women with ovarian masses and treatment of patients with epithelial ovarian (including fallopian tube and primary peritoneal) cancer. METHODS: A multidisciplinary, multinational ASCO Expert Panel reviewed existing guidelines, conducted a modified ADAPTE process, and conducted a formal consensus process with additional experts. RESULTS: Existing sets of guidelines from eight guideline developers were found and reviewed for resource-constrained settings; adapted recommendations from nine guidelines form the evidence base, informing two rounds of formal consensus; and all recommendations received ≥ 75% agreement. RECOMMENDATIONS: Evaluation of adult symptomatic women in all settings includes symptom assessment, family history, and ultrasound and cancer antigen 125 serum tumor marker levels where feasible. In limited and enhanced settings, additional imaging may be requested. Diagnosis, staging, and/or treatment involves surgery. Presurgical workup of every suspected ovarian cancer requires a metastatic workup. Only trained clinicians with logistical support should perform surgical staging; treatment requires histologic confirmation; surgical goal is staging disease and performing complete cytoreduction to no gross residual disease. In first-line therapy, platinum-based chemotherapy is recommended; in advanced stages, patients may receive neoadjuvant chemotherapy. After neoadjuvant chemotherapy, all patients should be evaluated for interval debulking surgery. Targeted therapy is not recommended in basic or limited settings. Specialized interventions are resource-dependent, for example, laparoscopy, fertility-sparing surgery, genetic testing, and targeted therapy. Multidisciplinary cancer care and palliative care should be offered. Additional information can be found at www.asco.org/resource-stratified-guidelines . It is ASCO's view that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines. [Media: see text]

18 March 2014 in Cancer
Verified
Journal Article
Open access
PDF file
RGRahel G. Ghebre
Rahel G. Ghebre
LJLovell A. Jones
Lovell A. Jones
JWJennifer A. Wenzel
Jennifer A. Wenzel
MMMichelle Y. Martin
Michelle Y. Martin
RDRaegan W. Durant
Raegan W. Durant
JFJean G. Ford
Jean G. Ford
BACKGROUND: Patient navigation programs are emerging that aim to address disparities in clinical trial participation among medically underserved populations, including racial/ethnic minorities. However, there is a lack of consensus on the role of patient navigators within the clinical trial process as well as outcome measures to evaluate program effectiveness.METHODS: A review of the literature was conducted of PubMed, Medline, CINHAL, and other sources to identify qualitative and quantitative studies on patient navigation in clinical trials. The search yielded 212 studies, of which only 12 were eligible for this review.RESULTS: The eligible studies reported on the development of programs for patient navigation in cancer clinical trials, including training and implementation among African Americans, American Indians, and Native Hawaiians. A low rate of clinical trial refusal (range, 4%‐6%) was reported among patients enrolled in patient navigation programs. However, few studies reported on the efficacy of patient navigation in increasing clinical treatment trial enrollment.CONCLUSIONS: Outcome measures are proposed to assist in developing and evaluating the efficacy and/or effectiveness of patient navigation programs that aim to increase participation in cancer clinical trials. Future research is needed to evaluate the efficacy of patient navigators in addressing barriers to clinical trial participation and increasing enrollment among medically underserved cancer patients. Cancer 2014;120(7 suppl):1122–30. © 2014 American Cancer Society.

1 August 2017 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
GRGeorge Ruzigana
George Ruzigana
LBLisa Bazzet-Matabele
Lisa Bazzet-Matabele
SRStephen Rulisa
Stephen Rulisa
AMAllison N. Martin
Allison N. Martin
RGRahel G. Ghebre
Rahel G. Ghebre
In limited resource settings such as Rwanda, visual inspection with acetic acid (VIA) is the primary model for cervical cancer screening. The objective of this study was to describe clinical characteristics and outcomes for women presenting for cervical cancer screening. A prospective, observational study was conducted between September 2015 and February 2016 at Kigali University Teaching Hospital (CHUK). Women referred to the VIA clinic were enrolled and completed a semi-structured questionnaire. During the six-month study period, 150 women were enrolled and evaluated with VIA followed by colposcopy directed biopsy for VIA positive. The median age was 42 years (IQR 36-49). Only 20 (13.3%) asymptomatic women presented for screening exam, whereas 126 (84%) were symptomatic. Among symptomatic patients, more than one-third had never had a speculum exam prior to referral (n = 43). Twenty-two (14.7%) women were VIA positive, and 8 (5.3%) had lesions suspicious for cancer, while 120 (80%) were found to be VIA negative. Among women undergoing biopsy (n = 30), 11 were normal (36.7%), 5 cases showed CIN 1 (16.6%), 4 cases showed CIN 2 (13.3%), 2 cases showed CIN 3 (6.7%) and 8 were confirmed cervical cancers (26.7%). In Rwanda, VIA is the current method for cervical cancer screening. In this study, few asymptomatic patients presented for cervical cancer screening. Increasing knowledge about cervical cancer screening and expanding access are key elements to improving cervical cancer control in Rwanda.

1 August 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
CNCharles Nkurunziza
Charles Nkurunziza
RGRahel Ghebre
Rahel Ghebre
UMUrania Magriples
Urania Magriples
DNDiomede Ntasumbumuyange
Diomede Ntasumbumuyange
LBLisa Bazzett-Matabele
Lisa Bazzett-Matabele
• Cervical cancer is the fourth most common cancer in women despite being a preventable disease. • Both patient and health system factors contribute to delay in diagnosis. • Lack of knowledge and facilities create a gap in cervical cancer screening and prevention services. • Coordinated effort is needed to integrate a functional cervical cancer prevention program into the Rwandan health system.